v3.25.4
SHARE-BASED COMPENSATION (Tables)
 12 Months Ended
Dec. 31, 2025
Share-Based Payment Arrangement [Abstract]  
Schedule of Compensation Expense and Related Tax Benefit for All Share-Based Awards
The following schedule presents compensation expense and the related tax benefit for all share-based awards:
(In millions)202520242023
Compensation expense$35 $31 $33 
Reduction of income tax expense10 7 9 
Summary of Weighted Average Value at Grant Date and the Significant Assumptions Used in Applying the Black-Scholes Model for Options Granted
The following schedule presents the weighted average grant date fair value and the significant assumptions used in the Black-Scholes model for these options:
202520242023
Weighted average value for options granted$— $— $11.23 
Weighted average assumptions used:
Expected dividend yield— %— %3.0 %
Expected volatility— %— %27.0 %
Risk-free interest rate— %— %4.00 %
Expected life (in years)0.00.04.5
Summary of Stock Option Activity
The following schedule presents our stock option activity for the three years ended December 31, 2025:
Number of sharesWeighted average exercise price
Balance at December 31, 20221,262,366 $50.75 
Granted291,005 52.90 
Exercised(95,207)29.67 
Expired(27,948)35.41 
Forfeited(9,838)57.07 
Balance at December 31, 20231,420,378 52.83 
Exercised(191,602)50.05 
Expired(103,008)46.84 
Forfeited(2,112)56.94 
Balance at December 31, 20241,123,656 53.85 
Exercised(127,836)50.21 
Expired(41,339)56.94 
Forfeited(2,097)52.90 
Balance at December 31, 2025952,384 54.20 
Outstanding stock options exercisable as of:
December 31, 2025859,825 54.34 
December 31, 2024869,716 52.61 
December 31, 2023891,884 50.36 
Summary of Additional Selected Information on Stock Options
The following schedule presents additional selected information on stock options at December 31, 2025:
Outstanding stock optionsExercisable stock options
 Exercise price range Number of sharesWeighted average exercise priceWeighted average remaining contractual life (years) Number of sharesWeighted average exercise price
$4.15 to $19.99
5,223 $6.41 
1
05,223 $6.41 
$40.00 to $44.99
1,974 43.07 0.41,974 43.07 
$45.00 to $49.99
384,929 47.35 1.6384,929 47.35 
$50.00 to $59.99
371,584 52.37 2.8279,025 52.20 
$60.00 to $73.22
188,674 73.22 3.0188,674 73.22 
952,384 54.20 
1
2.4859,825 54.34 
1 The weighted average remaining contractual life excludes 5,223 stock options without a fixed expiration date that were assumed in the Amegy acquisition. These options expire one year after the employee's termination date, subject to certain conditions.
Summary of Nonvested Restricted Stock Activity
The following schedule presents our restricted stock activity for the three years ended December 31, 2025:
Number of sharesWeighted average fair value
Nonvested restricted shares at December 31, 202260,749 $48.31 
Vested(24,978)46.31 
Nonvested restricted shares at December 31, 202335,771 49.71 
Issued49,019 41.24 
Vested(18,731)47.48 
Nonvested restricted shares at December 31, 202466,059 44.06 
Vested(24,034)44.83 
Nonvested restricted shares at December 31, 202542,025 43.61 
Summary of RSU Activity
The following schedule presents our RSU activity for the three years ended December 31, 2025:
Number of restricted stock unitsWeighted average fair value
Restricted stock units at December 31, 20221,169,093 $53.62 
Granted727,019 48.85 
Vested(522,163)48.71 
Forfeited(44,004)56.19 
Restricted stock units at December 31, 20231,329,945 52.88 
Granted872,274 39.53 
Vested(544,095)50.55 
Forfeited(34,621)48.78 
Restricted stock units at December 31, 20241,623,503 46.57 
Granted934,597 48.74 
Vested(616,219)48.49 
Forfeited(61,391)49.21 
Restricted stock units at December 31, 20251,880,490 46.93